High-Dose Stereotactic Radiation for Brain Cancer
(RAD1705 Trial)

Recruiting in Palo Alto (17 mi)

Dr. John Fiveash, MD - Birmingham, AL ...

Overseen byJohn B. Fiveash

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Alabama at Birmingham

No Placebo Group

Trial Summary

What is the purpose of this trial?This study looks at dose escalation for five fraction stereotactic radiotherapy for patients diagnosed with brain metastases with tumors 2.1-4.0 cm in diameter or 4.1-6.0 cm in diameter.

Eligibility Criteria

This trial is for adults over 18 with a confirmed cancer diagnosis and up to 10 brain metastases, as seen on an MRI. They must have a Karnofsky performance status of at least 60, indicating they can care for themselves. Participants need to consent in writing but cannot join if they've had surgery or prior radiation on the tumor, previous whole-brain irradiation, can't undergo MRI, received certain treatments within a week before the study starts, or have another large tumor.

Inclusion Criteria

All patients must have histologically confirmed malignancy

All patients must have imaging suggestive of one or more brain metastases

I am older than 18 years.

+3 more

Exclusion Criteria

I have had whole brain radiation before.

My second tumor is not larger than 3 cm.

My tumor has been treated with radiation before.

+4 more

Participant Groups

The study tests increasing doses of stereotactic radiosurgery delivered in five sessions for treating brain tumors that are between 2.1-6.0 cm in diameter. It aims to find out how much radiation can be safely given to shrink these tumors while sparing healthy tissue.

1Treatment groups

Experimental Treatment

Group I: Dose Escalated 5 Fraction Stereotactic RadiosurgeryExperimental Treatment1 Intervention

Patients will undergo dose escalated five fraction stereotactic radiosurgery for diagnosed brain metastases. Tumors must fall into one of two categories: 2.1-4.0cm diameter or 4.1-6.0 cm diameter. Only single largest tumor will be treated with dose escalation. All other tumors (if present) will be treated with standard of care five fraction stereotactic radiosurgery.